ME01614B - Farmaceutska kompozicija snažnog hcv inhibitora za oralnu primjenu - Google Patents

Farmaceutska kompozicija snažnog hcv inhibitora za oralnu primjenu

Info

Publication number
ME01614B
ME01614B MEP-2013-140A MEP14013A ME01614B ME 01614 B ME01614 B ME 01614B ME P14013 A MEP14013 A ME P14013A ME 01614 B ME01614 B ME 01614B
Authority
ME
Montenegro
Prior art keywords
pharmaceutical composition
oral administration
hcv inhibitor
hcv
inhibitor
Prior art date
Application number
MEP-2013-140A
Other languages
English (en)
Inventor
Feng-Jing Chen
Juan Francisco Gel
Maria Fernanda Villagra
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41650279&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME01614(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ME01614B publication Critical patent/ME01614B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MEP-2013-140A 2008-11-21 2009-11-18 Farmaceutska kompozicija snažnog hcv inhibitora za oralnu primjenu ME01614B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11678908P 2008-11-21 2008-11-21
EP09760395.5A EP2358355B1 (en) 2008-11-21 2009-11-18 Pharmaceutical composition of a potent hcv inhibitor for oral administration
PCT/US2009/064908 WO2010059667A1 (en) 2008-11-21 2009-11-18 Pharmaceutical composition of a potent hcv inhibitor for oral administration

Publications (1)

Publication Number Publication Date
ME01614B true ME01614B (me) 2014-09-20

Family

ID=41650279

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2013-140A ME01614B (me) 2008-11-21 2009-11-18 Farmaceutska kompozicija snažnog hcv inhibitora za oralnu primjenu

Country Status (35)

Country Link
US (2) US20120101049A1 (me)
EP (1) EP2358355B1 (me)
JP (1) JP5553839B2 (me)
KR (1) KR20110087297A (me)
CN (1) CN102223875A (me)
AR (1) AR074391A1 (me)
AU (1) AU2009316755B2 (me)
BR (1) BRPI0921070A2 (me)
CA (1) CA2738732A1 (me)
CL (1) CL2011000878A1 (me)
CO (1) CO6361900A2 (me)
CY (1) CY1114892T1 (me)
DK (1) DK2358355T3 (me)
EA (1) EA022272B1 (me)
EC (1) ECSP11011065A (me)
ES (1) ES2445516T3 (me)
HR (1) HRP20140097T1 (me)
IL (1) IL211832A (me)
MA (1) MA32812B1 (me)
ME (1) ME01614B (me)
MX (1) MX2011005151A (me)
MY (1) MY155402A (me)
NZ (1) NZ592383A (me)
PE (1) PE20120032A1 (me)
PL (1) PL2358355T3 (me)
PT (1) PT2358355E (me)
RS (1) RS53121B (me)
SG (1) SG171771A1 (me)
SI (1) SI2358355T1 (me)
TN (1) TN2011000258A1 (me)
TW (1) TWI469801B (me)
UA (1) UA105777C2 (me)
UY (1) UY32252A (me)
WO (1) WO2010059667A1 (me)
ZA (1) ZA201102029B (me)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
MY154683A (en) 2009-07-07 2015-07-15 Boehringer Ingelheim Int Pharmaceutical composition for a hepatitis c viral protease inhibitor
AU2011310761A1 (en) 2010-09-30 2013-02-21 Boehringer Ingelheim International Gmbh Combination therapy for treating HCV infection
MX2013003945A (es) * 2010-10-08 2013-06-05 Novartis Ag Formulaciones de vitamina e como inhibidoras de sulfamida ns3.
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
WO2012092411A2 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
CH707029B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
CN104244926A (zh) 2012-01-12 2014-12-24 勃林格殷格翰国际有限公司 作为强效的hcv 抑制剂的稳定的药物制剂
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013147749A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
EP2846778B1 (en) * 2012-05-07 2018-04-25 Bristol-Myers Squibb Holdings Ireland Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
ES2735355T3 (es) 2013-03-15 2019-12-18 Gilead Sciences Inc Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
WO2017062840A1 (en) * 2015-10-09 2017-04-13 Trek Therapeutics, Pbc Combination therapy for the treatment of hepatitis c virus
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
EP1461056A4 (en) * 2001-11-26 2006-01-25 Supergen Inc PROCESS FOR THE PREPARATION AND USE OF POLYOXYETHYLATED CICRIC OIL IN PHARMACEUTICAL COMPOSITIONS
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
MXPA05012545A (es) 2003-05-21 2006-02-08 Boehringer Ingelheim Int Compuestos inhibidores de la hepatitis c.
US7514557B2 (en) * 2004-05-25 2009-04-07 Boehringer Ingelheim International Gmbh Process for preparing acyclic HCV protease inhibitors

Also Published As

Publication number Publication date
CL2011000878A1 (es) 2011-09-02
TWI469801B (zh) 2015-01-21
CO6361900A2 (es) 2012-01-20
MY155402A (en) 2015-10-15
CN102223875A (zh) 2011-10-19
SG171771A1 (en) 2011-07-28
SI2358355T1 (sl) 2014-02-28
UA105777C2 (uk) 2014-06-25
CY1114892T1 (el) 2016-12-14
MA32812B1 (fr) 2011-11-01
EP2358355B1 (en) 2013-11-06
BRPI0921070A2 (pt) 2019-09-24
US20150038532A1 (en) 2015-02-05
AU2009316755A1 (en) 2010-05-27
EA022272B1 (ru) 2015-12-30
ECSP11011065A (es) 2011-06-30
WO2010059667A1 (en) 2010-05-27
JP5553839B2 (ja) 2014-07-16
KR20110087297A (ko) 2011-08-02
TW201023859A (en) 2010-07-01
PE20120032A1 (es) 2012-02-12
EP2358355A1 (en) 2011-08-24
IL211832A0 (en) 2011-06-30
AU2009316755B2 (en) 2015-10-08
PT2358355E (pt) 2014-01-08
PL2358355T3 (pl) 2014-04-30
MX2011005151A (es) 2011-05-30
EA201100795A1 (ru) 2012-01-30
ZA201102029B (en) 2011-11-30
UY32252A (es) 2010-06-30
IL211832A (en) 2015-02-26
JP2012509336A (ja) 2012-04-19
NZ592383A (en) 2012-11-30
TN2011000258A1 (en) 2012-12-17
AR074391A1 (es) 2011-01-12
DK2358355T3 (da) 2013-12-16
US20120101049A1 (en) 2012-04-26
ES2445516T3 (es) 2014-03-03
RS53121B (en) 2014-06-30
HRP20140097T1 (hr) 2014-03-14
CA2738732A1 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
ME01614B (me) Farmaceutska kompozicija snažnog hcv inhibitora za oralnu primjenu
HK1220902A1 (zh) 族群抑制劑之口服醫藥劑型
IL194277A (en) Zoladronic Acid Compounds for Oral Administration
ZA200900347B (en) Preparation of pharmaceutical compositions
AP2627A (en) New form of administration of racecadotril
EP2226071A4 (en) COMPOSITIONS FOR ORAL ADMINISTRATION
ZA201105572B (en) Pharmaceutical composition for oral administration
ZA200810178B (en) Pharmaceutical compositions for sustained release of phenyephrine
EP2263637A4 (en) MEDICINAL PREPARATION FOR ORAL ADMINISTRATION
IL208325A0 (en) Stabilizing lipis compositions for oral pharmaceutical agents
EP2407162A4 (en) COMPOSITION FOR ORAL ADMINISTRATION
IL202766A0 (en) Pharmaceutical combination of opioid and prostaglandin compound
ZA201102405B (en) Pharmaceutical composition for oral administration
EP2520300A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
PL2519261T3 (pl) Płynna kompozycja farmaceutyczna doustna nifedypiny
HK1115054A1 (en) Preparation for oral administration
GB0619891D0 (en) Pharmaceutical composition of risedronate
IL208967A (en) Oral Accenatide Preparations
GB0817431D0 (en) A capsule for oral administration